Entecavir therapy combined with DNA vaccination for persistent duck hepatitis B virus infection. - Wikidata - wikimedia - TriplyDB

Entecavir therapy combined with DNA vaccination for persistent duck hepatitis B virus infection.

Entecavir therapy combined with DNA vaccination for persistent duck hepatitis B virus infection.

http://www.wikidata.org/entity/Q35166065

about

The Discovery and Development of a Potent Antiviral Drug, Entecavir, for the Treatment of Chronic Hepatitis B Identification of anti-HBV activities in Paeonia suffruticosa Andr. using GRP78 as a drug target on Herbochip®.Effect of antiviral treatment with entecavir on age- and dose-related outcomes of duck hepatitis B virus infection.Covalently closed circular DNA is the predominant form of duck hepatitis B virus DNA that persists following transient infection.Immunotargeting with CD154 (CD40 ligand) enhances DNA vaccine responses in ducks.Residual integrated viral DNA after hepadnavirus clearance by nucleoside analog therapy.Therapeutic Antiviral Effect of the Nucleic Acid Polymer REP 2055 against Persistent Duck Hepatitis B Virus Infection.Entecavir for the treatment of chronic hepatitis B.Hepatocyte turnover during resolution of a transient hepadnaviral infection.Avian hepatitis B viruses: molecular and cellular biology, phylogenesis, and host tropism.Entecavir: a potent antiviral with minimal long-term resistance in nucleoside-naive chronic hepatitis B patients.Mouse models for therapeutic vaccination against hepatitis B virus.DNA vaccine: a promising new approach for chronic hepatitis B therapy.Present and future DNA vaccines for chronic hepatitis B treatment.Nucleic acid polymers prevent the establishment of duck hepatitis B virus infection in vivo.Investigational drugs in development for Hepatitis D.The Pekin duck programmed death-ligand 1: cDNA cloning, genomic structure, molecular characterization and mRNA expression analysis.Establishment and assessment of two methods for quantitative detection of serum duck hepatitis B virus DNA Combination of an antiviral drug and immunomodulation against hepadnaviral infection in the woodchuck model.Antiviral effects of PNA in duck hepatitis B virus infection model.Activity of nucleic acid polymers in rodent models of HBV infection.In vivo infectivity of liver extracts after resolution of hepadnaviral infection following therapy associating DNA vaccine and cytokine genes.

P2860

Q27007019-CB4BAADF-51E6-45D5-AD68-DA5FE5F04F53 Q33595736-F1DBF3AD-DD4F-4DC9-9A85-0F4AABC50788 Q33755065-04FA1668-244C-40D2-8326-9C195FB5C70B Q33984190-18BD04D8-BB3D-413E-A96B-E08AC230DCDC Q34975067-556A20BA-7141-40C4-97C4-9377719CC616 Q35735964-AB01E90A-C2C3-4E9B-8CA0-578006DE6DF7 Q35839139-63E956AA-953D-4082-A1AD-A3EDE1CA6D1C Q35964745-E0CAE533-D099-44EC-B0EA-01CB0DE159E1 Q36161444-5CED4421-9570-487E-B213-63B61ABBD41F Q36700708-74A792F4-F793-4CA0-A2C7-019BEB73CC7C Q37291331-F9A64417-F2CD-40A8-83A9-4865C0258768 Q38293590-98092BAC-6543-4ABA-95C8-23A672C1C7AA Q38604885-5344DF14-2259-4AD3-A2F5-65A9B86ACB7C Q38790065-9FE82495-A520-4BC4-890A-1A13FEC7CEAD Q39368000-1948B349-D247-493D-A173-089D42FCC5F0 Q40113645-2FB19F17-E832-4FD4-9276-6C8E5B0B1C06 Q41628406-03FB65A9-322F-45AB-8B9B-BA9A3A9B5331 Q41983135-72F01878-ED03-4BF8-BDFD-14FC1F926B2F Q43064406-7A7A63ED-B9E2-4323-8C22-9B07C9508FE3 Q45399993-7C99441F-0C7A-4E66-9F05-37C9B67DD29B Q46263692-10E5B31B-6304-4D13-BEE5-E43C460165DF Q46773926-3246466F-2F77-4A30-AA6E-FC84D303E57C

P2860

Entecavir therapy combined with DNA vaccination for persistent duck hepatitis B virus infection.

http://www.wikidata.org/entity/Q35166065

description

2003 nî lūn-bûn

@nan

2003 թուականի Օգոստոսին հրատարակուած գիտական յօդուած

@hyw

2003 թվականի օգոստոսին հրատարակված գիտական հոդված

@hy

2003年の論文

@ja

2003年論文

@yue

2003年論文

@zh-hant

2003年論文

@zh-hk

2003年論文

@zh-mo

2003年論文

@zh-tw

2003年论文

@wuu

name

Entecavir therapy combined wit ...... k hepatitis B virus infection.

@ast

Entecavir therapy combined wit ...... k hepatitis B virus infection.

@en

type

label

Entecavir therapy combined wit ...... k hepatitis B virus infection.

@ast

Entecavir therapy combined wit ...... k hepatitis B virus infection.

@en

prefLabel

Entecavir therapy combined wit ...... k hepatitis B virus infection.

@ast

Entecavir therapy combined wit ...... k hepatitis B virus infection.

@en

P1433

Q35166065-03C81C81-624E-424F-A4E3-D79D8A150486

P1476

Q35166065-F68F9710-275A-485A-ABC6-B5B7D5015D05

P2093

Q35166065-055265E0-52D7-49DE-BC20-C86A809AB42E

Q35166065-074A34B4-30EF-4CC0-9E55-52233B70DCAD

Q35166065-3867C468-C8C4-40A6-A6E5-38BAC6E7FD81

Q35166065-5A35B991-3DA7-4985-BDB4-36A2D6D325DE

Q35166065-93DE610A-D152-40D2-835E-D64830CCA6E0

Q35166065-A61898F6-7987-43EF-8070-5D86BA4008E9

P2860

Q35166065-076D29F5-7B9D-4A96-AF97-D18EBF18525E

Q35166065-10B88CBC-C4A1-40B5-A29E-D89FC5166501

Q35166065-14EA5967-CE58-41F9-987F-4254B7902CAD

Q35166065-1B7DD086-610B-4181-B9D8-F1A517D760A8

Q35166065-220660EE-E589-4B8D-8726-6DE78EF1620D

Q35166065-2336A621-CF2A-430B-AE91-DAA4DB786A0D

Q35166065-27179D2B-3FD3-4134-B072-98107CEC1049

Q35166065-290A66E9-9776-415D-9F15-CD9045916EF4

Q35166065-2B1F514B-7083-41A7-A092-0B088352B313

Q35166065-3A17C98E-5456-4F83-885A-A94D032A0C83

P304

Q35166065-E3F46625-4C34-4DA9-9B32-F412036958A2

P31

Q35166065-EDE8A971-7CDE-4701-923B-4AEE83447CE0

P356

Q35166065-A0AB6EF1-3EB4-48BE-BEA9-DDCA036409AA

P407

Q35166065-76E44C9B-39EA-4AAD-ACB8-1FB025EC4967

P433

Q35166065-991B7EB2-08F3-4629-B0BE-6DB45B76FCA9

P478

Q35166065-B8EE3980-7600-44E3-8D79-4766D9D3825C

P577

Q35166065-930B79BA-75D6-48AC-AAC0-D06A9C03B4AC

P5875

Q35166065-925C1B6D-E827-48C6-8472-35931BEBC7C1

P698

Q35166065-1C5EAC58-5CBD-4D57-9D96-3E3F3F6CF981

P932

Q35166065-92E9FC99-A169-4167-B29D-5395BBF78B69

P356

AAC.47.8.2624-2635.2003

P1433

Antimicrobial Agents and Chemotherapy

P1476

Entecavir therapy combined wit ...... k hepatitis B virus infection.

@en

P2093

Allison R Jilbert

http://www.w3.org/2001/XMLSchema#string

Darren S Miller

http://www.w3.org/2001/XMLSchema#string

Ieva Kotlarski

http://www.w3.org/2001/XMLSchema#string

Patricia L Marion

http://www.w3.org/2001/XMLSchema#string

Richard J Colonno

http://www.w3.org/2001/XMLSchema#string

Wendy K Foster

http://www.w3.org/2001/XMLSchema#string

P2860

Potent efficacy of entecavir (BMS-200475) in a duck model of hepatitis B virus replication.

Evidence that hepatocyte turnover is required for rapid clearance of duck hepatitis B virus during antiviral therapy of chronically infected ducks

Metabolic studies on BMS-200475, a new antiviral compound active against hepatitis B virus

Identification of BMS-200475 as a potent and selective inhibitor of hepatitis B virus

Structural and functional homology between duck and chicken interferon-gamma.

Long-term therapy with the guanine nucleoside analog penciclovir controls chronic duck hepatitis B virus infection in vivo.

Inhibition of duck hepatitis B virus replication by 9-(2-phosphonylmethoxyethyl)adenine, an acyclic phosphonate nucleoside analogue

Protective efficacy of DNA vaccines against duck hepatitis B virus infection.

Enhanced T-cell immunogenicity and protective efficacy of a human immunodeficiency virus type 1 vaccine regimen consisting of consecutive priming with DNA and boosting with recombinant fowlpox virus.

Duck hepatitis B virus replication in primary bile duct epithelial cells.

P304

2624-2635

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1128/AAC.47.8.2624-2635.2003

http://www.w3.org/2001/XMLSchema#string

P407

P433

8

http://www.w3.org/2001/XMLSchema#string

P478

47

http://www.w3.org/2001/XMLSchema#string

P577

2003-08-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

10646003

http://www.w3.org/2001/XMLSchema#string

P698

12878529

http://www.w3.org/2001/XMLSchema#string

P932

166090

http://www.w3.org/2001/XMLSchema#string